Modi et al. showed promising clinical antitumor activity of trastuzumab deruxtecan (T-DXd) in patients considered to be HER2-low or heterogeneous, probably due to the high levels of payload delivered in HER2-expressing cancer cells when compared with other anti-HER2 therapies [24]. This evidence concerns the gene ERBB2 and cancer.